+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hodgkin's Lymphoma - Opportunity Analysis and Forecasts to 2029

  • ID: 5118471
  • Report
  • June 2020
  • Region: Global
  • 140 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • ADC Therapeutics
  • Beigene
  • Genmab
  • ImmunoGen
  • Ono Pharmaceuticals
  • Takeda
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

HL is a rare hematological malignancy that arises from the lymphatic system. Although HL is a rare condition, it has a high cure rate due to the positive response to treatment which combines chemotherapy, targeted therapy, radiotherapy and stem cell transplant accordingly. The World Health Organization (WHO) classifies HL into two main types: classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL), which CHL accounts for 95% of cases. Historically, treatment of HL has been mostly reliant on chemotherapies, radiotherapy and SCT and has lacked a rapidly advancing pipeline.

In recent years however, the arrival of three novel agents reflect a change in the treatment paradigm, shifting from cytotoxic therapies to immunotherapies and novel cell-based therapies. The publisher is expecting a total of 6 new entrants to launch over the forecast period in the 8MM from 2019-2029, while specific marketed agents are expected to move into earlier lines of treatment as novel combinations. The main competition will between drug entering the first-line setting and novel combinations within the salvage setting for relapsed and refractory patients. Given the high cure rate for this indication, these two early setting are the most determinant of global sales for Hodgkin’s lymphoma.

Key Highlights
  • The main drivers of growth include the anticipated label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of the market leading drugs and the lack of premium priced therapeutics entering the market.
  • Among the late-stage pipeline products and marketed agents, marketed drug combinations and CAR-T cell therapies are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the Hodgkin’s lymphoma market include: improving cure rates in the first-line treatment setting, more options available for relapsed and refractory patients and alternative treatments to stem cell transplants.

KEY QUESTIONS ANSWERED
  • Six late-stage pipeline agents are going to enter Hodgkin lymphoma market from 2019 onwards. What the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in Hodgkin’s lymphoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope
  • Overview of Hodgkin’s lymphoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Hodgkin’s lymphoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Hodgkin’s lymphoma therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global Hodgkin’s lymphoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Hodgkin’s lymphoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hodgkin’s lymphoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Hodgkin’s lymphoma therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ADC Therapeutics
  • Beigene
  • Genmab
  • ImmunoGen
  • Ono Pharmaceuticals
  • Takeda

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Hodgkin’s Lymphoma: Executive Summary
2.1 Moderate Market Growth Expected for Hodgkin’s Lymphoma During 2019-2029
2.2 Drug Developers Focusing On Combination Therapies Featuring Marketed Products with Novel Therapies
2.3 Need for More Effective Therapies to Reduce the Use of Chemotherapy and Delay Stem Cell Transplant is Partially Attainable
2.4 Growth in the 8MM Is Driven by Label Expansions of Existing Therapies and Less Impacted by Novel Agents
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Diagnosis and Symptoms
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Sources Not Used
5.5 Forecast Assumptions and Methods
5.5.1 8MM
5.6 Epidemiological Forecast for HL (2019-2029)
5.6.1 Diagnosed Incident Cases of HL
5.6.2 Diagnosed Incident Cases of Classical HL
5.6.3 Age-Specific Diagnosed Incident Cases of Classical HL
5.6.4 Sex-Specific Diagnosed Incident Cases of Classical HL
5.6.5 Diagnosed Incident Cases of Classical HL by Cancer Stage
5.6.6 Diagnosed Incident Cases of Classical HL by Cancer Subtypes
5.6.7 Five-Year Diagnosed Prevalent Cases of Classical HL
5.6.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant HL
5.7 Discussion
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of the Analysis
5.7.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Treatment Overview
7 Unmet Needs and Opportunity Assessment8 R&D Strategies9 Pipeline Assessment10 Pipeline Valuation Analysis11 Appendix
List of Tables
Table 1: Hodgkin’s Lymphoma: Key Metrics in the 8MM
Table 2: Characteristics of the Five Histologic Subtypes of HL
Table 3: Notable Somatic Alterations Identified in RS cells of HL
Table 4: The Lugano Staging Classification of HL
Table 5: Prognostic Risk Factors of HL
Table 6: HL Cancer Stages
Table 7: Risk Factors and Comorbidities for HL
Table 8: Treatment Guidelines for HL
Table 9: Leading Treatments for HL, 2019
Table 10: List of Key Historical Clinical Trials of Marketed Products in HL
Table 11: List of Ongoing Key Clinical Trials for Marketed Products
Table 12: Comparison of Therapeutic Classes in Development for HL, 2019-2029
Table 13: Innovative Early Stage Approaches for HL
Table 14: Drugs in Development for HL, 2020
Table 15: Clinical Benchmark of Key Pipeline Drugs - HL
Table 16: Commercial Benchmark of Key Pipeline Drugs - HL
Table 17: Key Events Impacting Global Sales for HL, 2019-2029
Table 18: HL Global Market - Global Drivers and Barriers, 2019 and 2029
Table 19: HL US Market - Global Drivers and Barriers, 2019 and 2029
Table 20: HL 5EU Market - Global Drivers and Barriers, 2019 and 2029
Table 21: HL Japan Market - Global Drivers and Barriers, 2019 and 2029
Table 22: HL China Market - Global Drivers and Barriers, 2019 and 2029
Table 23: Key Historical and Projected Launch Dates for HL
Table 24: Key Historical and Projected Patent Expiry Dates for HL
Table 25: Adult Average Weight per Country Based on National Studies
Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Sales Forecast by Class for HL in the US in 2019 and 2029
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Adcetris
Figure 3: 8MM, Diagnosed Incidence Rates of CHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009?2029
Figure 4: Sources Used for Diagnosed Incident Cases of HL, CHL, and NLPHL
Figure 5: Sources Used for Diagnosed Incident Cases of CHL by Stage
Figure 6: Sources Used for Diagnosed Incident Cases of CHL Subtypes
Figure 7: Sources Used for Five-Year Diagnosed Prevalent Cases of CHL
Figure 8: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019
Figure 9: 8MM, Diagnosed Incident Cases of CHL, Both Sexes, All Ages, N, 2019
Figure 10: 8MM, Age-Specific Diagnosed Incident Cases of CHL, Both Sexes, N, 2019
Figure 11: 8MM, Sex-Specific Diagnosed Incident Cases of CHL, All Ages, N, 2019
Figure 12: 8MM, Diagnosed Incident Cases of CHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019
Figure 13: 8MM, Diagnosed Incident Cases of CHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019
Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of CHL, Both Sexes, All Ages, N, 2019 and 2029
Figure 15: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019
Figure 16: Treatment Overview for HL
Figure 17: Unmet Needs and Opportunities in HL
Figure 18: Overview of the Development Pipeline in HL
Figure 19: Key Phase II and III Trials for the Promising Pipeline Agents that the Publisher Expects be Licensed for HL in the 8MM During the Forecast Period
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Adcetris
Figure 21: Global (8MM) Sales Forecast by Country for HL in 2019 and 2029
Figure 22: Global (8MM) Sales Forecast by Class for HL in 2019 and 2029
Figure 23: Sales Forecast by Class for HL in the US in 2019 and 2029
Figure 24: Global Sales Forecast by Class in the 5EU for HL in 2019 and 2029
Figure 25: Global Sales Forecast by Class in Japan for HL in 2019 and 2029
Figure 26: Global Sales Forecast by Class in China for HL in 2019 and 2029
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bristol-Myers Squibb
  • Merck Co
  • Seattle Genetics
  • Affimed
  • RAPT Therapeutics
  • Hanmi Pharmaceuticals
  • Ono Pharmaceuticals
  • Takeda
  • Innovent
  • Eli Lilly
  • Jiangsu Hengrui
  • Beigene
  • Tessa Therapeutics
  • ADC Therapeutics
  • Genmab
  • Trillium Therapeutics
  • Cstone Pharmaceuticals
  • Aurigene
  • Immunagen
  • Harbin Gloria Pharmaceuticals
  • Arcus Biosciences
  • Zhengda Tianqing
  • Regeneron Pharmaceuticals
  • Genzyme
  • ImmunoGen
Note: Product cover images may vary from those shown